Evogene shares surge 17.25% intraday after Biomica subsidiary secures exclusive global licensing agreement for BMC128 microbiome therapy in kidney and lung cancer with Shanghai Lishan Biopharma, showing promising Phase 1 trial results.

Evogene surged 17.25% intraday as its subsidiary Biomica signed an exclusive global licensing agreement with Shanghai Lishan Biopharmaceuticals for BMC128, a microbiome therapy for kidney cancer and non-small cell lung cancer currently in Phase 1 clinical trials showing promising safety and early efficacy. Under the agreement, Biomica is eligible for development and sales milestone payments, as well as future royalties based on clinical progress, regulatory approvals, and product sales. Evogene, a computational chemistry company specializing in small molecule design for the pharmaceutical and agricultural industries, develops BMC128, a four-strain human gut microbiome therapy aimed at enhancing immunotherapy responses and stimulating anti-tumor activity.